# PepGen

Type: Company (PEPG)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/pepgen
Canonical HTML page: https://gethealthbrief.com/entity/pepgen

## Timeline

- **2026-03-05**: Earnings Release — Both companies report Q4 and FY 2025 financial results and business highlights.
- **2026-03-04**: FDA Partial Hold — FDA notifies PepGen of partial clinical hold on Freedom2 trial.
- **2025-12-31**: Fiscal Year End — OmniAb and PepGen conclude their 2025 fiscal years.

## Recent coverage (2 stories)

### OmniAb and PepGen 2025 Results Clouded by FDA Hold on Freedom2 Trial
2026-03-05 05:48:11 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.
Full story: https://gethealthbrief.com/story/omniab-pepgen-2025-earnings-fda-hold

### GeneDx and PepGen Set for Critical Earnings as Genomic Adoption Scales
2026-02-21 07:54:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

GeneDx and PepGen are scheduled to report quarterly financial results on Monday, marking a pivotal moment for the genomic diagnostics and neuromuscular biotech sectors. Investors are looking for GeneDx's continued path toward profitability through whole genome sequencing and PepGen's clinical pipeline progress.
Full story: https://gethealthbrief.com/story/genedx-pepgen-earnings-preview-genomic-diagnostics

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.